- Issuer ticker
-
RLAY
- Reported as of
-
13 Jan 2026
- Net transaction value
-
$0
- SEC form
-
4
- Accepted by SEC
-
15 Jan 2026, 16:13:30 UTC
Filing notes and source
Key filing fact
Sanjiv Patel filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 15 Jan 2026.
Key facts
- This page summarizes Sanjiv Patel's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Jan 2026, 16:13.
Change
- Previous filing in this sequence was filed on 07 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001816210
Primary reporting owner
Patel Sanjiv
- Relationship
-
President and CEO, Director
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RLAY
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,450,000
- Change %
- Price
-
$0.000000
- Shares after
- 1,450,000
- Date
- 13 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,450,000
- Exercise price
- $7.94
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote